Shots: The company will not expand the P-II EMERGE study that assesses Vopratelimab + ipilimumab in PD-(L)1 inhibitor experienced NSCLC patient. Early evaluation of the study showed that the trial […]readmore
Tags : Jounce Therapeutics
The 2020 JP Morgan Healthcare Conference was loaded with insights from key pharma companies. An analysis of events and catalysts that were announced or updated at the conference these days […]readmore
Shots: Jounce to receive $50M up front, $180M as development & regulatory milestones, $300M as commercial milestones, royalties on global sales and will retain WW rights to its pipeline including […]readmore